Supernus Pharmaceuticals Q2 2024 GAAP EPS $0.36 Beats $0.05 Estimate, Sales $168.300M Beat $148.851M Estimate
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 2024 GAAP EPS of $0.36, significantly beating the analyst estimate of $0.05. The company also reported sales of $168.3 million, surpassing the $148.851 million estimate and marking a 24.15% increase from the same period last year.
August 06, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals reported Q2 2024 GAAP EPS of $0.36, beating the $0.05 estimate by 620%. Sales were $168.3M, exceeding the $148.851M estimate and showing a 24.15% YoY increase.
The significant beat on both EPS and sales estimates, along with a strong year-over-year sales increase, is likely to positively impact SUPN's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100